US 12,472,217 B2
Platform oncolytic vector for systemic delivery
Stephen H. Thorne, Pittsburgh, PA (US); Daniel J. Byrd, Pittsburgh, PA (US); and Mingrui Zhang, Pittsburgh, PA (US)
Assigned to Kalivir Immunotherapeutics, Inc., Pittsburgh, PA (US)
Filed by KaliVir Immunotherapeutics, Inc., Pittsburgh, PA (US)
Filed on Jan. 14, 2022, as Appl. No. 17/575,787.
Application 17/575,787 is a continuation of application No. 17/192,736, filed on Mar. 4, 2021.
Application 17/192,736 is a continuation of application No. 16/759,705, previously published as PCT/US2018/058456, filed on Oct. 31, 2018.
Claims priority of provisional application 62/579,517, filed on Oct. 31, 2017.
Prior Publication US 2022/0125865 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/768 (2015.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01)
CPC A61K 35/768 (2013.01) [A61P 35/00 (2018.01); C07K 14/7158 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12Y 302/01035 (2013.01)] 22 Claims
 
1. An oncolytic virus, wherein the oncolytic virus comprises:
an exogenous nucleic acid that codes for a chemokine receptor or a functional variant thereof, wherein the chemokine receptor or the functional variant thereof induces cellular chemotaxis towards a chemokine ligand, and wherein the exogenous nucleic acid that codes for the chemokine receptor or the functional variant thereof is inserted into a viral genome of the oncolytic virus; and
an exogenous nucleic acid that codes for an antibody or antibody fragment.